About Mirus Bio
Mirus Bio is a company based in Madison (United States) founded in 1995 was acquired by Sigma Aldrich in May 2024.. Mirus Bio offers products and services including TransIT-VirusGEN® Transfection Reagent, TransIT® -AAViator™ Transfection System, and Rev IT™AAV Enhancer. Mirus Bio operates in a competitive market with competitors including Avidity Biosciences, Ultragenyx, Alnylam, Gemini Therapeutics and BioMarin Pharmaceutical, among others.
- Headquarter Madison, United States
-
Sectors
HealthcareTechnology
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mirus Bio, Llc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$155.09 K (USD), Grant
Sep 05, 2008
-
Investors
Roche
& 5 more
-
Employee Count
Employee Count
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Mirus Bio
Mirus Bio offers a comprehensive portfolio of products and services, including TransIT-VirusGEN® Transfection Reagent, TransIT® -AAViator™ Transfection System, and Rev IT™AAV Enhancer. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enhances delivery of plasmids for viral vector production.
Optimizes AAV production for gene therapy applications.
Increases AAV titers in various cell lines and media.
Unlock access to complete
Funding Insights of Mirus Bio
- Total Funding Total Funding
- Total Rounds 3
- Last Round Grant — $155,085
-
First Round
First Round
(06 Oct 2004)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2008 | Amount | Grant - Mirus Bio | Valuation |
investors |
|
| Aug, 2007 | Amount | Grant - Mirus Bio | Valuation |
investors |
|
| Oct, 2004 | Amount | Grant - Mirus Bio | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Mirus Bio
Mirus Bio has secured backing from 6 investors, including institutional investors. Prominent investors backing the company include Roche, NIH and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Federal innovation and scientific achievement services are provided.
|
Founded Year | Domain | Location | |
|
Drug discovery services are provided to the biopharma sector.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Mirus Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Mirus Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Mirus Bio Comparisons
Competitors of Mirus Bio
Mirus Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Ultragenyx, Alnylam, Gemini Therapeutics and BioMarin Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Developer of precision therapeutics for dry AMD and rare genetic diseases
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Mirus Bio
Frequently Asked Questions about Mirus Bio
When was Mirus Bio founded?
Mirus Bio was founded in 1995 and raised its 1st funding round 9 years after it was founded.
Where is Mirus Bio located?
Mirus Bio is headquartered in Madison, United States. It is registered at Madison, Wisconsin, United States.
What does Mirus Bio do?
Mirus Bio was founded in 1995 in Madison, United States, within the biotechnology sector. Transfection reagents and electroporation products are developed for molecular and cell biology applications. The product range includes TransIT-VirusTransfection Reagent and Kits, along with tools for virus production and transduction. Delivery systems are offered to support research in these areas. Operations focus on providing solutions for gene delivery and related processes.
Who are the top competitors of Mirus Bio?
Mirus Bio's top competitors include Alnylam, Avidity Biosciences and BioMarin Pharmaceutical.
What products or services does Mirus Bio offer?
Mirus Bio offers TransIT-VirusGEN® Transfection Reagent, TransIT® -AAViator™ Transfection System, and Rev IT™AAV Enhancer.
Who are Mirus Bio's investors?
Mirus Bio has 6 investors. Key investors include Roche, NIH, HHS, Sigma Aldrich, and SBIR.